Novo Nordisk acquired Inversago Pharma for ~£ ... Prior to Heligan, he served as a senior director at Clearwater and spent five years at 3i Private Equity. His early career includes eight years ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk itself is preparing to release clinical trial results on CagriSema's ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s largest by market capitalization. Steven Goldstein is based in London ...

Kristian Tuxen Ladegaard Berg / SOPA Images / LightRocket / Getty Images The U.S.-listed shares of Danish drugmaker Novo Nordisk (NVO) rose Tuesday following a report that an activist investor is ...

(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity ...

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.” The supercomputer, named Gefion ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge fund Parvus Asset Management is building a stake in the Danish drugmaker ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR ...

It isn't wise to count out this veteran pharmaceutical company, however. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why.

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown for compounders to stop selling their versions of semaglutide.